Patents by Inventor Emma HAJAJ

Emma HAJAJ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modulation of SLAMF6 splice variants for cancer therapy
    Patent number: 11834487
    Abstract: The invention relates to cancer immunotherapy, particularly to improved therapeutic modalities involving specifically modulating the expression and/or activity of SLAMF6 splice variants. More specifically, embodiments of the invention provide compositions and methods for cancer therapy, including adoptive T cell transfer therapies, cell vaccines and/or polypeptide- based medicaments. In various embodiments, compositions and methods providing selective augmentation of SLAMF6 variant 3 (SLAMF6var3) N expression or activity on T cells and/or tumor cells are provided.
    Type: Grant
    Filed: February 11, 2019
    Date of Patent: December 5, 2023
    Assignee: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD.
    Inventors: Michal Lotem, Galit Mishan Eisenberg, Emma Hajaj
  • COMBINATION CANCER IMMUNOTHERAPY
    Publication number: 20220370558
    Abstract: The invention relates to cancer management, specifically to therapeutic combinations and methods for immunotherapy of tumors and malignancies. More specifically, embodiments of the invention provide compositions, methods, pharmaceutical packages and combined preparations employing the use of a SLAMF6-mediated T cell activator in combination with a LAG3 inhibitor.
    Type: Application
    Filed: June 23, 2020
    Publication date: November 24, 2022
    Inventors: Michal Lotem, Emma Hajaj, Galit Eisenberg
  • NUCLEIC ACID AGENTS MODULATING SLAMF6 ISOFORMS
    Publication number: 20220347203
    Abstract: The invention relates to nucleic acid agents modulating the expression of SLAMF6 isoforms, compositions comprising same and methods for their use in immunomodulation. Specifically, provided are splice-switching oligonucleotides and constructs useful in cancer immunotherapy.
    Type: Application
    Filed: June 23, 2020
    Publication date: November 3, 2022
    Inventors: Michal Lotem, Emma Hajaj, Galit Eisenberg
  • MODULATION OF SLAMF6 SPLICE VARIANTS FOR CANCER THERAPY
    Publication number: 20210054043
    Abstract: The invention relates to cancer immunotherapy, particularly to improved therapeutic modalities involving specifically modulating the expression and/or activity of SLAMF6 splice variants. More specifically, embodiments of the invention provide compositions and methods for cancer therapy, including adoptive T cell transfer therapies, cell vaccines and/or polypeptide- based medicaments. In various embodiments, compositions and methods providing selective augmentation of SLAMF6 variant 3 (SLAMF6var3) N expression or activity on T cells and/or tumor cells are provided.
    Type: Application
    Filed: February 11, 2019
    Publication date: February 25, 2021
    Inventors: Michal LOTEM, Galit MISHAN EISENBERG, Emma HAJAJ